美国主动脉研究联盟中开窗与分支腔内主动脉修复术的趋势和结局随时间变化
该研究回顾性分析了2015至2023年间10个前瞻性、非随机、医生发起的器械豁免研究中2377例开窗与分支腔内主动脉修复术(F/B-EVAR)患者。结果显示,尽管修复范围和复杂性增加,技术失败率、不良事件率和再干预率保持稳定;30天主要不良事件(MAE)发生率为10%,1年再干预率为18%。
要点
- F/B-EVAR可安全实施且结局可接受,尽管修复范围和复杂性增加,技术失败、不良事件和再干预率保持稳定。
- 30天MAE发生率为10%,调整后30天生存率为99.6%。
- 1年再干预率为18%,患者特异性器械使用与再干预风险降低相关。
核心结论
- 来自美国多个中心的数据表明,F/B-EVAR可以安全实施且结局可接受。
- 尽管修复范围和复杂性增加,技术失败率、不良事件率和再干预率保持稳定,可能部分归因于微创技术的演进。
研究设计与样本
- 回顾性研究了2015年至2023年间在参与美国主动脉研究联盟的中心实施的F/B-EVAR。
- 研究纳入10个前瞻性、非随机、医生发起的器械豁免研究中的F/B-EVAR病例,共2377例患者。
- 采用混合效应多因素回归模型分析结局决定因素,并使用调整的观察值减期望值累积和(CUSUM)分析评估随时间变化的结局。
主要发现
- 研究期间胸腹主动脉瘤比例(P = .01)和主动脉夹层比例(P = .001)增加,而技术失败率(P = .6)和住院时间(P = .1)保持稳定。
- 融合成像(P = .0005)、低剖面器械(P < .0001)和完全经股动脉修复(P = .0005)的使用随时间增加。
- 透视时间、手术时间、辐射剂量和失血量在整个研究期间均下降(所有P < .0001)。
- 调整后30天生存率为99.6%(IQR,99.3%-99.8%),240例(10%)发生MAE。
- MAE的决定因素包括年龄(OR,1.3/10年;95%CI,1.1-1.6;P = .005)、估算肾小球滤过率(OR,0.9/10 mL/min/1.73 m2;95%CI,0.82-0.95;P = .001)、胸腹主动脉瘤(OR,1.8;95%CI,1.3-2.6;P = .002)、手术时间(OR,1.04/10分钟;95%CI,1.03-1.06;P < .0001)和技术失败(OR,3.0;95%CI,1.7-5.1;P = .0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize trends and outcomes with fenestrated and branched endovascular aortic repair (F/B-EVAR) performed at centers participating in the US Aortic Research Consortium. METHODS: F/B-EVARs performed in 10 prospective, nonrandomized, physician-sponsored investigative device exemption studies from 2015 to 2023 were studied retrospectively. Outcomes included 30-day major adverse event (MAE) and 1-year secondary reintervention. Outcome determinants were modeled with mixed effects multivariable regression. Adjusted observed minus expected cumulative sum analysis was used to evaluate outcomes achieved over time. RESULTS: In the study period, 2377 patients underwent F/B-EVAR. The median follow-up was 2.3 years (interquartile range [IQR], 0.7-3.5 years). The proportion of thoracoabdominal aneurysms (P = .01) and aortic dissections (P = .001) increased over the study period while technical failure rates (P = .6) and length of hospital stay (P = .1) remained stable. Fusion imaging (P = .0005), low-profile devices (P < .0001), and completely transfemoral repair (P = .0005) were adopted increasingly over time. There were decreases in fluoroscopy time, procedure time, radiation dosage, and blood loss throughout the study (all P < .0001). Adjusted 30-day survival was 99.6% (IQR, 99.3%-99.8%) and MAE occurred in 240 (10%). MAE determinants included age (odds ratio [OR], 1.3 per 10-years; 95% confidence interval [CI], 1.1-1.6; P = .005), estimated glomerular filtration rate (OR, 0.9 per 10-mL/min/1.73 m2; 95% CI, 0.82-0.95; P = .001), thoracoabdominal aneurysm (OR, 1.8; 95% CI, 1.3-2.6; P = .002), operative time (OR, 1.04 per 10 minutes; 95% CI, 1.03-1.06; P < .0001), and technical failure (OR, 3.0; 95% CI, 1.7-5.1; P = .0001). The cumulative rate of 30-day MAE remained stable, reflecting expected outcomes rates. The 1-year reintervention rate was 18% (n = 435). Secondary intervention determinates included patient-specific device use (OR, 0.4; 95% CI, 0.28-0.65; P = .045), technical failure (OR, 3.1; 95% CI, 1.9-5.3; P < .0001), total target vessels (OR, 1.3 per vessel; 95% CI, 1.05-1.6; P = .002), and prior aortic dissection (OR, 1.9; 95% CI, 1.3-2.6; P = .0005). The cumulative rate of 1-year reintervention remained stable during the study period. CONCLUSIONS: Data from multiple US centers demonstrate that F/B-EVAR can be performed safely and with acceptable outcomes. Despite increasing repair extent and complexity, the rates of technical failure, adverse events, and reintervention remained stable, likely driven, in part, by evolutions in minimally invasive techniques.
引用
- Finnesgard EJ, Jones DW, Beck AW, et al. Trends and outcomes over time with fenestrated and branched endovascular aortic repair in the United States Aortic Research Consortium. J Vasc Surg. 2025. PMID: 39914755. doi:10.1016/j.jvs.2025.01.213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。